Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - August 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 28 August 2025, 10:00 (CEST) to 28 August 2025, 11:00 (CEST)

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - September 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 September 2025, 10:00 (CEST) to 18 September 2025, 11:00 (CEST)

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - October 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 14 October 2025, 11:00 (CEST) to 14 October 2025, 12:00 (CEST)

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - November 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2025, 11:00 (CET) to 18 November 2025, 12:00 (CET)

Questions and answers clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - December 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 December 2025, 11:00 (CET) to 18 December 2025, 12:00 (CET)

Human medicines European public assessment report (EPAR): Uplizna, inebilizumab, Date of authorisation: 25/04/2022, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Winlevi, clascoterone, Status: Opinion under re-examination

EMEA-003049-PIP01-21-M01

EMEA-000639-PIP03-16-M03

HMPC: overview of assessment work - priority list